Mary Caffrey

Levittown

Executive Editor at MJH Life Sciences

Jersey politics and sports. No work zone.

Featured in: Favicon

mjhlifesciences.com

linkedin.com Favicon

patch.com

newsbreak.com Favicon

ajmc.com

pharmacytimes.com Favicon

onclive.com Favicon

realclearpolicy.com Favicon

curetoday.com Favicon

managedhealthcareexecutive.com + 8 more

Articles

Tech Updates: McKesson Launches Precision Oncology Consortium; Financing for RISA Labs PA Platform

1 week ago | ajmc.com | Mary Caffrey

McKesson on Wednesday launched a precision oncology initiative to guide practices as they move more heavily toward biomarker-driven cancer care.
Trump’s Stance Doesn’t End Need for Diversity in Clinical Trials

1 week ago | asianamericans.einnews.com | Mary Caffrey

In December 2024, Rachel E. Rau, MD, brightened when asked about data that showed a new regimen for pediatric leukemia worked exceptionally well in Hispanic children.1Rau, an associate professor of pediatrics at Seattle Children’s, shared results that showed adding blinatumomab (Blincyto; Amgen Inc) to chemotherapy boosted disease-free survival by 61% in children with B-cell acute lymphoblastic leukemia.
Trump’s Stance Doesn’t End Need for Diversity in Clinical Trials

1 week ago | ajmc.com | Mary Caffrey

In December 2024, Rachel E. Rau, MD, brightened when asked about data that showed a new regimen for pediatric leukemia worked exceptionally well in Hispanic children.1Rau, an associate professor of pediatrics at Seattle Children’s, shared results that showed adding blinatumomab (Blincyto; Amgen Inc) to chemotherapy boosted disease-free survival by 61% in children with B-cell acute lymphoblastic leukemia.
Sutter Health, SCAN Announce Partnership to Launch New MA Products, Joint Venture Health Plan

1 week ago | ajmc.com | Mary Caffrey

Sutter Health, an integrated health care system in Northern California, and SCAN Group, a not-for-profit company rooted in bringing better care to seniors, on Thursday announced a collaboration to bring Medicare Advantage (MA) products to Northern California and, if approved, launch a new joint venture health plan. Sutter, based in Sacramento, California, covers 3.5 million people while the SCAN Health Plan covers more than 300,000 members in California, Arizona, Nevada, New Mexico, and Texas.
Will the Coming Radiopharmaceutical Wave Reach More Patients With Cancer?

2 weeks ago | ajmc.com | Mary Caffrey

Rising interest in solutions that target cancer therapies directly has fueled growth in radiopharmaceuticals, a sector witnessing new studies, banner trial results, and, most recently, an FDA approval that promises to greatly expand who can receive treatment. Radiopharmaceuticals pinpoint delivery of radionuclides to targeted lesions to diagnose and treat multiple diseases.
As Court Action Heats Up, Study Shows More Money Made on 340B in Wealthy Areas

3 weeks ago | ajmc.com | Mary Caffrey

A drug discount program that Congress created to support safety net hospitals is generating windfalls for participants who push its reach into wealthy areas, according to results from a new study. The study, by the National Pharmaceutical Council (NPC) and appearing in the journal Inquiry,1 examined how geography, facility characteristics, and a hospital’s market power affected profit margins under the 340B program, which was created by the Public Health Service Act of 1992.
Updated KRYSTAL-7 Data Show PFS Beyond 27 Months for Adagrasib Plus Pembro in First-line Treatment of KRAS-mutated NSCLC

3 weeks ago | ajmc.com | Mary Caffrey

Use of the targeted therapy adagrasib with the immunotherapy pembrolizumab allowed certain patients with newly diagnosed KRASG123-mutated non–small cell lung cancer (NSCLC) to live more than 27 months without disease progression, according to data presented Thursday at the European Lung Cancer Conference in Paris, France.1 Updated results from the phase 2 KRYSTAL-7 trial (NCT04613596) evaluated adagrasib (Krazati; Mirati Therapeutics) and pembrolizumab (Keytruda; Merck) in patients harboring...
Amid NIH Cuts, ASH Expands Eligibility for Midcareer Research Awards

1 month ago | ajmc.com | Mary Caffrey

The American Society of Hematology (ASH) has expanded the criteria for its midcareer research award to allow more investigators to apply, including those cut off from funding through the National Institutes of Health (NIH) due tox the “evolving landscape” under the second Trump administration. The ASH Bridge Grant, which historically provides investigators up to $150,000 for a year, will no longer be limited to those who have applied for the NIH’s basic research project grant, known as NIH R01.
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot

1 month ago | ajmc.com | Mary Caffrey |Rose McNulty

Texas Oncology, a community oncology giant with nearly 1000 providers across 280 locations, announced today it would form a multiyear partnership with Canopy, a continuous care platform that helps practices electronically collect and manage patient feedback, with the goal of preventing hospital stays and improving outcomes.
Cancer Labels on Alcohol? Ireland, Where Pubs Still Rule, Will Have Them by Next Year

1 month ago | ajmc.com | Mary Caffrey

St. Patrick’s Day falls on a Monday this year, meaning the holiday honoring the 5th century missionary concludes a weekend of parades, parties, and—of course—drinking. Alcohol’s hold on a day that recalls the arrival of Christianity in Ireland has always created some irony.